Rothschild & Co. Asset Management US Inc. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 764,082 shares of the biopharmaceutical company’s stock after selling 856 shares during the quarter. Rothschild & Co. Asset Management US Inc.’s holdings in Gilead Sciences were worth $49,673,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. grew its stake in Gilead Sciences by 2.2% in the 4th quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after buying an additional 2,195,948 shares during the last quarter. Vanguard Group Inc grew its position in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after purchasing an additional 1,071,619 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Gilead Sciences by 5,733.7% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 28,491,386 shares in the last quarter. Northern Trust Corp grew its position in shares of Gilead Sciences by 2.3% during the 4th quarter. Northern Trust Corp now owns 16,987,641 shares of the biopharmaceutical company’s stock worth $1,062,577,000 after purchasing an additional 380,928 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Gilead Sciences by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 16,867,065 shares of the biopharmaceutical company’s stock worth $1,053,332,000 after purchasing an additional 835,915 shares in the last quarter. 78.71% of the stock is currently owned by institutional investors.

Shares of NASDAQ GILD traded up $2.00 during trading hours on Monday, hitting $64.25. 232,548 shares of the stock were exchanged, compared to its average volume of 5,958,029. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $79.36 billion, a price-to-earnings ratio of 10.45, a P/E/G ratio of 0.76 and a beta of 1.09. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted $1.48 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, June 13th. This represents a $2.52 annualized dividend and a dividend yield of 3.92%. Gilead Sciences’s dividend payout ratio is 40.98%.

GILD has been the topic of a number of analyst reports. Citigroup restated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 5th. Wells Fargo & Co decreased their target price on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 5th. Raymond James set a $90.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Maxim Group set a $84.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Finally, BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $79.54.

In related news, Director Richard James Whitley sold 9,534 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the sale, the director now owns 34,669 shares in the company, valued at approximately $2,270,126.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total transaction of $173,178.00. Following the sale, the director now owns 57,560 shares in the company, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. Insiders have sold a total of 28,602 shares of company stock worth $1,863,445 in the last quarter. 0.20% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-sold-by-rothschild-co-asset-management-us-inc/3030327.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Blockchain

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.